Intravitreal Dexamethasone Implant for Persistent Macular Thickening and Edema After Vitrectomy for Epiretinal Membrane

Stopped early · Not applicable

Conditions studied: Macular Edema, Epiretinal Membrane, Vitrectomy

In brief

This study seeks to evaluate the effect of the intravitreal 0.7mg dexamethasone implant on central macular thickness and visual acuity in those patients with persistent macular edema after pars plana vitrectomy for epiretinal membrane.

Key facts

Study ID

NCT02995746

Run by

Wills Eye

People needed

3

Starts

2016-01-28

Expected to finish

2017-09-14

Last updated by the study team

2018-10-03

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patient of the Wills Eye Institute Retina service, including all Mid-Atlantic Retina offices
• Volunteer patients age 18 years and older
• Healthy enough to participate in the study
• Willing and able to consent to participation in the study
• History of pars plan vitrectomy for symptomatic epiretinal membrane at least 3 months prior to study enrollment date
• BCVA of 20/40 or worse
• CMT of at least 400 micrometers with or without cystoid macular edema on SD-OCT
• Prior treatment with topical NSAIDs without resolution of macular thickening or visual acuity improvement

You may not qualify if…

• Advanced glaucoma (cup-disc ratio of 0.8 or greater)
• History of glaucoma filtering or tube shunt implant surgery
• Steroid responsive intraocular hypertension
• Diabetic retinopathy
• History of uveitis
• Use of systemic or intraocular corticosteroids
• Active or suspected ocular or periocular infections
• Other confounding intraocular pathology

Where it is running

• Mid Atlantic Retina — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.